ArticleAmerican journal of cancer research2025
Surgical outcomes and prognostic factors of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the surgical outcomes and prognostic factors of neoadjuvant chemotherapy (NACT) combined with interval debulking surgery (IDS) in patients with advanced ovarian cancer.
methodsA retrospective analysis was conducted on clinical data of 97 patients with advanced ovarian cancer admitted to Xijing Hospital of The Fourth Military Medical University from January 2018 to December 2019. The patients were divided into two groups based on their treatment methods: a control group (primary debulking surgery (PDS), n=48) and an observation group (NACT combined with IDS, n=49). Short-term efficacy, perioperative outcomes, tumor markers, immune function, quality of life, adverse reactions, and survival status were compared between the two groups. Factors affecting prognosis were analyzed, a Nomogram prediction model was constructed and validated.
resultsThe observation group demonstrated superior short-term efficacy than the control group, with lower intraoperative blood loss, shorter hospitalization duration, and reduced transfusion volume (
conclusionNACT combined with IDS demonstrated superior short-term efficacy compared to traditional PDS in patients with advanced ovarian cancer, with improved perioperative conditions, reduced adverse reactions, and enhanced survival rates. Age, tumor size, histological differentiation, and treatment modality independently affect patient prognosis. The Nomogram prediction model developed in this study demonstrates excellent discriminative power and clinical applicability for prognostic evaluation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.